H.R. 9090: Advancing Menopause Care and Mid-Life Women’s Health Act

This bill, titled the **Advancing Menopause Care and Mid-Life Women's Health Act**, aims to enhance the care and health outcomes for women experiencing menopause and related conditions. The key components of the bill include:

1. Research and Innovation

The bill authorizes the National Institutes of Health (NIH) to:

• Coordinate and expand research focused on the health impacts of menopause and related symptoms, aiming to understand their effects on physical, mental, and cognitive health.
• Study the prevention of adverse health outcomes during the menopausal transition.
• Address known health disparities between different demographics, such as rural and urban women.
• Develop integrated approaches to menopause care, which may involve both medication and non-medical treatments.
• Award grants to various eligible entities to support research and innovation in treatments for perimenopause and menopause-related conditions.

2. Public Health Promotion and Prevention

The Secretary of Health and Human Services will expand efforts to promote public health regarding mid-life women's health, focusing on:

• Detecting and treating menopausal symptoms and chronic conditions effectively.
• Increasing access to quality care and improving health outcomes through grants awarded to states, local health departments, and educational institutions.
• Enhancing mental health support and substance use prevention services for women experiencing menopause-related issues.

3. Awareness and Education Programs

The bill includes provisions for a national awareness campaign about menopause and mid-life women's health, which entails:

• Disseminating educational materials to healthcare providers, patients, and public health stakeholders.
• Conducting outreach programs that are culturally appropriate and tailored to different communities, particularly targeting underserved populations.
• Creating online resources to provide accessible information regarding menopause and women's health.

4. Training Programs for Healthcare Providers

A key aspect of the bill is the establishment of training programs related to menopause care:

• Grants will be awarded to entities to develop or expand training programs for healthcare professionals focusing on the management of menopausal symptoms.
• These programs may include residency programs, fellowships, and other types of clinical training.

5. Designation of Centers of Excellence

The bill allows for the designation of **Centers of Excellence** in menopause care, which will:

• Receive grants to improve training resources for health providers.
• Focus on the development of evidence-based resources about the care and treatment of menopausal symptoms.

6. Reporting and Coordination

The Secretary of Health and Human Services is tasked with:

• Submitting reports detailing the progress and effectiveness of activities under this Act.
• Coordinating with other federal efforts related to menopausal symptoms and women's health.
• Addressing identified barriers to care and proposing solutions to address health disparities.

7. Funding Provisions

The bill authorizes appropriations to support its initiatives. $25 million per year from 2027 through 2031 is allocated for NIH-related research, while $10 million a year is designated for public health awareness and training programs.

Relevant Companies

• PFE (Pfizer Inc.): As a pharmaceutical company, Pfizer may be impacted by the increased focus on developing new treatments for menopause symptoms and related health conditions.
• ABT (Abbott Laboratories): Abbott may benefit from grants related to diagnostic testing and innovative treatment development for menopause-related health issues.
• MDT (Medtronic PLC): Potential involvement in developing medical devices or technologies for menopausal symptom management may arise as a result of the enhanced research and education efforts mandated by the bill.